Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Lonza Will Expand Viral Therapy Plant …
by Rick Mullin
June 22, 2015
| A version of this story appeared in
Volume 93, Issue 25
The contract manufacturer Lonza plans to construct a 100,000-sq-ft facility near Houston that will double its capacity to produce viral gene therapies and virally modified cell therapies. The project will add eight clean rooms for 2,000-L-scale production in single-use bioreactors. Lonza, which already manufactures viral-based products at the site, did not disclose the amount of the investment. It hopes to open the facility in early 2017.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X